Interesting article on patience centric drug development in cancer (general) here nejm.org/doi/full/10.1056/N...
Key quote: "...a fundamental shift in cultural orientation among drug developers and regulatory reviewers is imperative. Specifically, the patient experience of treatment with a given drug must be regarded as essential information about the properties of the product, without which our understanding of its risk–benefit profile is incomplete."
So true